The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

The oligomer hypothesis for Alzheimer's disease (AD) was introduced in 1998. It was based
on evidence that oligomers could exist free of amyloid fibrils, that fibril-free oligomer …

Converging lines of evidence suggest that progressive accumulation of the amyloid β‐
protein (Aβ) plays a central role in the genesis of Alzheimer's disease, but it was long …

The amyloid hypothesis has driven drug development strategies for Alzheimer's disease for
over 20 years. We review why accumulation of amyloid-beta (Aβ) oligomers is generally …

Protein aggregation is common to dozens of diseases including prionoses, diabetes,
Parkinson's and Alzheimer's. Over the past 15 years, there has been a paradigm shift in …

Alzheimer's disease (AD) is the 3rd most costly disease and the leading cause of dementia.
It can linger for many years, but ultimately is fatal, the 6th leading cause of death …

J. Neurochem.(2012) 120 (Suppl. 1), 125–139. Abstract For nearly 100 years following the
first description of this neurological disorder by Dr Alois Alzheimer, amyloid plaques and …

The'toxic Aβ oligomer'hypothesis has attracted considerable attention among Alzheimer's
disease researchers as a way of resolving the lack of correlation between deposited amyloid …

A large body of clinical and nonclinical evidence supports the role of neurotoxic soluble beta
amyloid (amyloid, Aβ) oligomers as upstream pathogenic drivers of Alzheimer's disease …

Alzheimer's disease (AD) is a common neurodegenerative disease characterized by
amyloid plaque and neurofibrillary tangles (NFT). With the finding that soluble nonfibrillar Aβ …